Manuel Nico Dold
Research Subjects
Manuel Nico Dold has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Andrej Rasch
Verband Forschender Arzneimittelhersteller e.V., Berlin, Germany
1 shared publication - Astrid Genet
Pfizer Deutschland GmbH, Berlin, Germany
1 shared publication Eva-Maria Reuter
AMS Advanced Medical Services GmbH, Munich, Germany
1 shared publication- Jessica Schmelcher
AMS Advanced Medical Services GmbH, Munich, Germany
1 shared publication - Klaus Gossens
AbbVie Deutschland, Wiesbaden, Germany
1 shared publication - Maria Katharina Schweitzer
AMS Advanced Medical Services GmbH, Munich, Germany
1 shared publication
Latest Publications
- Open Access
- 16 October 2023
- Published by Springer Nature in The European Journal of Health Economics
- Vol. 25 (5) , 877-888
Shaping a suitable EU HTA dossier template: why the German template is not fit for purpose
From 2025, Health Technology Developers (HTDs) have to submit EU HTA dossiers. The joint clinical assessment (JCA) aims to streamline HTA processes and access to medicinal products across Europe. Currently, German HTA bodies IQWiG and G-BA actively shape the JCA methodology. Here we examine if German HTA dossier requirements are suitable for the JCA. We compare the number of safety endpoint and subgroup analyses in German dossiers with analyses considered in IQWIG’s benefit assessment and evaluate if these analyses were considered by the G-BA. We further investigated how the number of analyses was affected by the latest change in the German dossier template. With the current template, HTDs report in median 2.6 times more analyses on adverse events (AE) and 1.1 times more subgroup categories than in the previous template. IQWiG does not consider 33% of AE analyses and 73% of the subgroup categories presented by the HTD under the current template. G-BA considered the same AE as IQWiG in 76% of cases. Subgroups were uncommented by G-BA in most cases, independent of the template (previous: 93%, current 85%) and unconsidered in the conclusion on additional benefit (previous: 77%, current 69%). Thus, changes in the dossier template drastically increased HTD workload, but additional analyses seem unconsidered by the HTA bodies. With a broader scope in JCA, this effect could be amplified. To mitigate duplicative efforts and ensure prompt availability of medicinal products as envisioned by the HTAR, we suggest well-chosen and precise dossier requirements, early consultations, and early HTD engagement.
- 16 October 2023
- Published by Springer Nature in The European Journal of Health Economics
- Vol. 25 (5) , 877-888
Open AccessShaping a suitable EU HTA dossier template: why the German template is not fit for purpose
From 2025, Health Technology Developers (HTDs) have to submit EU HTA dossiers. The joint clinical assessment (JCA) aims to streamline HTA processes and access to medicinal products across Europe. Currently, German HTA bodies IQWiG and G-BA actively shape the JCA methodology. Here we examine if German HTA dossier requirements are suitable for the JCA. We compare the number of safety endpoint and subgroup analyses in German dossiers with analyses considered in IQWIG’s benefit assessment and evaluate if these analyses were considered by the G-BA. We further investigated how the number of analyses was affected by the latest change in the German dossier template. With the current template, HTDs report in median 2.6 times more analyses on adverse events (AE) and 1.1 times more subgroup categories than in the previous template. IQWiG does not consider 33% of AE analyses and 73% of the subgroup categories presented by the HTD under the current template. G-BA considered the same AE as IQWiG in 76% of cases. Subgroups were uncommented by G-BA in most cases, independent of the template (previous: 93%, current 85%) and unconsidered in the conclusion on additional benefit (previous: 77%, current 69%). Thus, changes in the dossier template drastically increased HTD workload, but additional analyses seem unconsidered by the HTA bodies. With a broader scope in JCA, this effect could be amplified. To mitigate duplicative efforts and ensure prompt availability of medicinal products as envisioned by the HTAR, we suggest well-chosen and precise dossier requirements, early consultations, and early HTD engagement.